Persistent diarrhoea, hypotension, polyneuropathy;Perzistentní průjmy, hypotenze a polyneuropatie

Vnitrni Lekarstvi

Volumn 54, Issue 11, 2008, Pages 1106-1110

  Sykora R ^a   Radej J ^a   Novak I ^a   Krouzecky A ^a   Mares J ^a   Irova I ^a   Hadravska S ^a   Chvojka, J ^a   Karvunidis, T ^a   Manakova T ^a   Matějovič, Martin ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Amyloidosis; Biopsy; Diarrhoea; Hypotension; Polyneuropathy; Renal insufficiency

Indexed keywords

MIDODRINE; TERLIPRESSIN;

ADULT; AMYLOIDOSIS; ANAMNESIS; ARTICLE; AUTOPSY; CASE REPORT; CLINICAL FEATURE; DIARRHEA; DISEASE COURSE; HUMAN; HYPOTENSION; KIDNEY BIOPSY; KIDNEY FAILURE; MALE; MULTIPLE ORGAN FAILURE; POLYNEUROPATHY;

AMYLOIDOSIS; DIARRHEA; FEMALE; HUMANS; HYPOTENSION; MIDDLE AGED; POLYNEUROPATHIES;

EID: 57149083503     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Westermark P, Benson MD, Buxbaum JN et al. Nomenclature Committee of the International Society of Amyloidosis. Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid 2005; 12: 1-4.
2. Adam Z, Ščudla V. Klinické projevy a diagnostika AL-amyloidózy a nékterých dalších typů amyloidóz. Vnitř Lék 2001; 47: 36-45.
3. Brychta T, Pařenica J, Zatočil T et al. Restriktivní kardiomyopatie jako projev primární amyloidózy. Vnitř Lék 2004; 50: 66-71.
4. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45-59.
5. Maysouye I. Diagnostic screening of systemic amyloidosis by abdominal fat aspiration: an analysis of 100 cases. Am J Dermatopathol 1997; 19: 41-45.
6. Li K, Kyle RA, Dyck PJ. Immunohistochemical characterization of amyloid proteins in sural nerves and clinical associations in amyloid neuropathy. Am J Pathol 1992; 141: 217-226.
7. Hazenberg BP, Bijzet J, Limburg PC et al. Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid 2007; 14: 133-140.
8. Ryšavá R. Perspektivy: Současné terapeutické postupy u amyloidózy ledvin. Postgrad Nefrol 2006; 4: 50-51.
9. Dember LM. Emerging treatment approaches for the systemic amyloidoses. Kidney Int 2005; 68: 1377-1390.
10. Lachmann H, Obici L, Berber L et al. Results of multi-center, randomized, placebo-controlled trial for the treatment of amyloid A (AA) amyloidosis associated renal disease with NC-503 (eprodisate disodium). Nephrol Dial Transplant 2006; 21 (Suppl 4): iv294.
11. Gillmore JD, Hawkins PN. Drug insight: emerging therapies for amyloidosis. Nature Clin Pract Nephrol 2006; 2: 263-270.
12. Wechalekar AD, Hawkins PN, Gillmore JD. Perspectives in treatment of A Lamyloidosis. Br J Haematol 2008; 140: 365-377.
13. Palladini G, Russo P, Nuvolone M et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007; 110: 787-788.
14. Dispenzieri A, Gertz MA, Kyle RA et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 3751-3757.
15. Bohle A, Wehrmann R, Eissele R et al. The long-term prognosis of AA and AL renal amyloidosis and the pathogenesis of chronic renal failure in renal amyloidosis. Path Res Pract 1993; 189: 316-331.
16. Hachulla E, Grateau G. Diagnostic tools for amyloidosis. Joint Bone Spine 2002; 69: 538-545.
17. Kebbel A, Röcken C. Immunohistochemical classification of amyloid in surgical pathology revisited. Am J Surg Pathol 2006; 30: 673-683.
18. Freeman R. Autonomic dysfunction. In: Samuels M, Feske S (eds). The Office Practice of Neurology. 2nd ed. Philadelphia: Churchill-Livingstone 2003; 14: 145.